Intra- and intersubject variability: mixed-effects statistical analysis of repeated doses of an angiotensin converting enzyme inhibitor, CGS 16617.
The intrasubject and intersubject variabilities for CGS 16617, an angiotensin converting enzyme inhibitor, were evaluated in an open-label, repeat single-dose bioavailability trial. Eight healthy male volunteers each received a 20-mg oral dose of CGS 16617 as an aqueous solution on four separate occasions. Components of variance were evaluated for a mixed-effects statistical model in which subjects were regarded as a random factor. While intersubject variability was statistically significant (P less than 0.05) for all pharmacokinetic variables measured, AUC, Cmax, t1/2, and tmax, its contribution to the total observed variability was relatively small for AUC, t1/2, and tmax. The proportion of variation due to intrasubject variability was 70, 19, 61, and 72% for AUC, Cmax, t1/2, and tmax, respectively. Ramifications of the large intrasubject source component of variability as related to bioavailability trials and biological variation are discussed.
Kochak
G M
GM
Clinical Pharmacokinetics Section, Pharmaceuticals Division, CIBA-GEIGY, New York 10502.
Smith
R A
RA
Choi
R L
RL
John
V
V
Tipnis
V
V
Honc
F
F
deSilva
J K
JK
Weidler
D J
DJ
D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000493:pharmacokinetics*; D001552:Benzazepines / Q000493:pharmacokinetics*; D006207:Half-Life; D006801:Humans; D008297:Male; D008954:Models, Biological; D013223:Statistics as Topic
D000806:Angiotensin-Converting Enzyme Inhibitors; D001552:Benzazepines; C052134:libenzapril